Stock 002399 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Equities

002399

CNE100000P02

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 12/05/2024 BST 		5-day change 1st Jan Change
10.21 CNY -0.39% Intraday chart for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. -7.43% -12.96%
04-29 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-02 Shenzhen Hepalink Receives Thai Approval for Blood Clot Drug Exarane MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Shenzhen Hepalink Receives Thai Approval for Blood Clot Drug Exarane
Thailand Food and Drug Administration Approves for Sales in the Market of Exarane Produced by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s Wholly-Owned Subsidiary Shenzhen Techdow Medicine Co., Ltd
Shenzhen Hepalink Pharmaceutical Widens 2023 Loss as Revenue Drops 24%
Shenzhen Techdow Medicine Co., Ltd., Wholly-Owned Subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Exarane Obtains Approval from New Zealand Medicines and Medical Devices Safety Authority
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces No Final Dividend for the Year Ended 31 December 2023
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Hepalink Pharmaceutical Gets Lifeline from Controlling Shareholder
Shenzhen Hepalink Forecasts Loss in 2023; Shares Slide 4%
Shenzhen Hepalink Flags Provisions of Up to 950 Million Yuan; Shares Fall 4%
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023
Hepalink Pharmaceutical's Profit Drops 86% in Q3; Shares Slump 4%
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Hepalink Pharmaceutical's H1 Attributable Profit Plunges on Higher Share of Losses from Associates
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Change of Financial Controller from Mr. Xiang Xianqing to Ms. Chen Juan
Shenzhen Hepalink Pharmaceutical’s H1 Profit to Fall By Up to 81%
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on July 18, 2023
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2022
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announce Payment of Dividend on H Shares for the Year Ended December 31, 2022, Payable on May 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002399 Stock
  4. News Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  5. Other languages